Cognitive deficits and functional outcomes in major depressive disorder: Determinants, substrates, and treatment interventions

Depression and Anxiety

Volumn 30, Issue 6, 2013, Pages 515-527

  McIntyre, Roger S ^a,b,c   Cha, Danielle S ^c   Soczynska, Joanna K ^c   Woldeyohannes, Hanna O ^b   Gallaugher, Laura Ashley ^b   Kudlow, Paul ^b   Alsuwaidan, Mohammad ^c   Baskaran, Anusha ^b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

cognitive deficits; cognitive dysfunction; dementia; duloxetine; functional outcome; major depressive disorder; vortioxetine

Indexed keywords

ATTENTION; COGNITIVE DEFECT; EXECUTIVE FUNCTION; HUMAN; MAJOR DEPRESSION; MEDLINE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOSOCIAL DISORDER; REVIEW; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 84878757053     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22063     Document Type: Review

References (96)

1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU,. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 2012.
2. van RA, Huffmeier J, Victor D, Klocke K, Borlinghaus J, Pawelzik M,. Contrasting chronic with episodic depression: an analysis of distorted socio-emotional information processing in chronic depression. J Affect Disord 2012.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64 (12): 1465-1475.
4. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006; 163 (9): 1561-1568.
5. Jaeger J, Berns S, Uzelac S, Davis-Conway S,. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res 2006; 145 (1): 39-48.
6. Conradi HJ, Ormel J, de JP,. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2010 Oct. 8: 1-10.
7. Buist-Bouwman MA, Ormel J, de GR, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand 2008; 118 (6): 451-458.
8. Reppermund S, Zihl J, Lucae S, et al. Persistent cognitive impairment in depression: the role of psychopathology and altered hypothalamic-pituitary- adrenocortical (HPA) system regulation. Biol Psychiatry 2007; 62 (5): 400-406.
9. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Abarca JE, et al. Major depressive disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery. J Affect Disord 2010; 123 (1-3): 341-350.
10. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164 (6): 900-909.
11. Millan MJ, Agid Y, Brune M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012; 11 (2): 141-168.
12. Airaksinen E, Wahlin A, Forsell Y, Larsson M,. Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up. Acta Psychiatr Scand 2007; 115 (6): 458-465.
13. Furtado CP, Hoy KE, Maller JJ, Savage G, Daskalakis ZJ, Fitzgerald PB,. An investigation of medial temporal lobe changes and cognition following antidepressant response: a prospective rTMS study. Brain Stimul 2012 Jul 6; 1e9.
14. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A,. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand 2012; 125 (4): 281-292.
15. McLennan SN, Mathias JL,. The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review. Int J Geriatr Psychiatry 2010; 25 (10): 933-944.
16. Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, et al. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res 2010; 177 (3): 323-329.
17. Herrera-Guzman I, Gudayol-Ferre E, Lira-Mandujano J, et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res 2008; 160 (1): 72-82.
18. Ferguson JM, Wesnes KA, Schwartz GE,. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003; 18 (1): 9-14.
19. Larochette AC, Harrison AG, Rosenblum Y, Bowie CR,. Additive neurocognitive deficits in adults with attention-deficit/hyperactivity disorder and depressive symptoms. Arch Clin Neuropsychol 2011; 26 (5): 385-395.
20. Cserjesi R, Luminet O, Poncelet AS, Lenard L,. Altered executive function in obesity. Exploration of the role of affective states on cognitive abilities. Appetite 2009; 52 (2): 535-539.
21. Aas M, Steen NE, Agartz I, et al. Is cognitive impairment following early life stress in severe mental disorders based on specific or general cognitive functioning ? Psychiatry Res 2012 Apr 1; 198 (3): 495-500.
22. Martinez-Aran A, Vieta E, Colom F, et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 2000; 69 (1): 2-18.
23. Martinez-Aran A, Vieta E, Reinares M, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004; 161 (2): 262-270.
24. Grut M, Jorm AF, Fratiglioni L, Forsell Y, Viitanen M, Winblad B,. Memory complaints of elderly people in a population survey: variation according to dementia stage and depression. J Am Geriatr Soc 1993; 41 (12): 1295-1300.
25. Naismith SL, Longley WA, Scott EM, Hickie IB,. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 2007; 7: 32.
26. Gualtieri CT, Morgan DW,. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J Clin Psychiatry 2008; 69 (7): 1122-1130.
27. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA,. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord 2012; 140 (2): 113-124.
28. Jones RN, Manly J, Glymour MM, Rentz DM, Jefferson AL, Stern Y,. Conceptual and measurement challenges in research on cognitive reserve. J Int Neuropsychol Soc 2011 Mar 17; 17 (4): 593-601.
29. Godard J, Baruch P, Grondin S, Lafleur MF,. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study. Psychiatry Res 2012; 196 (1): 145-153.
30. Preiss M, Kucerova H, Lukavsky J, Stepankova H, Sos P, Kawaciukova R,. Cognitive deficits in the euthymic phase of unipolar depression. Psychiatry Res 2009; 169 (3): 235-239.
31. Simons CJ, Jacobs N, Derom C, et al. Cognition as predictor of current and follow-up depressive symptoms in the general population. Acta Psychiatr Scand 2009; 120 (1): 45-52.
32. Gorwood P, Corruble E, Falissard B, Goodwin GM,. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008; 165 (6): 731-739.
33. Singh-Manoux A, Akbaraly TN, Marmot M, et al. Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II study. J Clin Psychiatry 2010; 71 (10): 1379-1385.
34. MacQueen GM, Campbell S, McEwen BS, et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci U S A 2003; 100 (3): 1387-1392.
35. Snyder HR,. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 2012 May 28; 139 (1): 81-132.
36. Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011; 475 (7354): 27-30.
37. Kiosses DN, Klimstra S, Murphy C, Alexopoulos GS,. Executive dysfunction and disability in elderly patients with major depression. Am J Geriatr Psychiatry 2001; 9 (3): 269-274.
38. Kim JM, Stewart R, Glozier N, et al. Physical health, depression and cognitive function as correlates of disability in an older Korean population. Int J Geriatr Psychiatry 2005; 20 (2): 160-167.
39. McCall WV, Dunn AG,. Cognitive deficits are associated with functional impairment in severely depressed patients. Psychiatry Res 2003; 121 (2): 179-184.
40. Sweeney JA, Kmiec JA, Kupfer DJ,. Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol Psychiatry 2000; 48 (7): 674-684.
41. Krishnan V, Nestler EJ,. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010; 167 (11): 1305-1320.
42. Jiao Q, Ding J, Lu G, et al. Increased activity imbalance in fronto-subcortical circuits in adolescents with major depression. PLoS One 2011; 6 (9): e25159.
43. Pizzagalli DA,. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011; 36 (1): 183-206.
44. Sandstrom A, Sall R, Peterson J, et al. Brain activation patterns in major depressive disorder and work stress-related long-term sick leave among Swedish females. Stress 2012; 15 (5): 503-513.
45. Malykhin NV, Carter R, Hegadoren KM, Seres P, Coupland NJ,. Fronto-limbic volumetric changes in major depressive disorder. J Affect Disord 2012; 136 (3): 1104-1113.
46. Andreazza AC,. Combining redox-proteomics and epigenomics to explain the involvement of oxidative stress in psychiatric disorders. Mol Biosyst 2012 Jun 18; 8 (10): 2503-2512.
47. Drevets WC, Price JL, Furey ML,. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008; 213 (1-2): 93-118.
48. Yucel K, Nazarov A, Taylor VH, Macdonald K, Hall GB, MacQueen GM,. Cerebellar vermis volume in major depressive disorder. Brain Struct Funct 2012; Jun 14.
49. Stahl SM, Zhang L, Damatarca C, Grady M,. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003; 64 (Suppl 14): 6-17.
50. Malykhin NV, Carter R, Seres P, Coupland NJ,. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci 2010; 35 (5): 337-343.
51. Zeng LL, Shen H, Liu L, et al. Identifying major depression using whole-brain functional connectivity: a multivariate pattern analysis. Brain 2012; 135 (Pt 5): 1498-1507.
52. Li M, Soczynska JK, Kennedy SH,. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatry Rep 2011; 13 (5): 316-320.
53. Ryan JP, Sheu LK, Critchley HD, Gianaros PJ,. A neural circuitry linking insulin resistance to depressed mood. Psychosom Med 2012; 74 (5): 476-482.
54. Kessing LV, Jorgensen OS,. Apolipoprotein E-epsilon 4 frequency in affective disorder. Biol Psychiatry 1999; 45 (4): 430-434.
55. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006; 63 (2): 161-167.
56. Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012; 169 (5): 523-530.
57. McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009; 9 (1): 51-59.
58. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S,. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011; 68 (1): 51-57.
59. McIntyre RS, Vagic D, Swartz SA, et al. Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. CNS Drugs 2008; 22 (6): 443-453.
60. Craft S, Watson GS,. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3 (3): 169-178.
61. Minzenberg MJ, Yoon JH, Carter CS,. Modafinil modulation of the default mode network. Psychopharmacology (Berlin) 2011; 215 (1): 23-31.
62. Mars RB, Neubert FX, Noonan MP, Sallet J, Toni I, Rushworth MF,. On the relationship between the "default mode network" and the "social brain." Front Hum Neurosci 2012; 6: 189.
63. Kenna H, Hoeft F, Kelley R, et al. Fasting plasma insulin and the default mode network in women at risk for Alzheimer's disease. Neurobiol Aging 2012; Jul 5; 34 (3): 641-649.
64. Muller N, Schwarz MJ,. Immunological aspects of depressive disorders. Nervenarzt 2007; 78 (11): 1261-1273.
65. Xu Z, Zhang Z, Shi Y, et al. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response. J Affect Disord 2011; 133 (1-2): 165-173.
66. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE,. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res 2009; 43 (9): 855-863.
67. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011; 54 (9): 3206-3221.
68. Katona C, Hansen T, Olsen CK,. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27 (4): 215-223.
69. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F,. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15 (5): 589-600.
70. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340 (3): 666-675.
71. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood) 1999; 18 (5): 163-171.
72. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289 (23): 3095-3105.
73. Kessler RC, Merikangas KR, Wang PS,. The prevalence and correlates of workplace depression in the national comorbidity survey replication. J Occup Environ Med 2008; 50 (4): 381-390.
74. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE,. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 2010; 27 (1): 78-89.
75. van EP, van WG, Fernandez G, et al. Amygdala responsivity related to memory of emotionally neutral stimuli constitutes a trait factor for depression. Neuroimage 2011; 54 (2): 1677-1684.
76. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006; 67 (11): 1754-1759.
77. Blank T, Prinz M,. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 2012; Jun 27; 61 (1): 62-70.
78. Bowie CR, Harvey PD,. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 2005; 28 (3): 613-633, 626.
79. Bowie CR, McGurk SR, Mausbach B, Patterson TL, Harvey PD,. Combined cognitive remediation and functional skills training for schizophrenia: effects on cognition, functional competence, and real-world behavior. Am J Psychiatry 2012; May 11.
80. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am J Psychiatry 2010; 167 (9): 1116-1124.
81. Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E,. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008; 18 (11): 787-793.
82. Bora E, Yucel M, Pantelis C,. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009; 113 (1-2): 1-20.
83. Chan A, Shea TB,. Effects of dietary supplementation with N-acetyl cysteine, acetyl-L-carnitine and S-adenosyl methionine on cognitive performance and aggression in normal mice and mice expressing human ApoE4. Neuromolecular Med 2007; 9 (3): 264-269.
84. Vasques PE, Moraes H, Silveira H, Deslandes AC, Laks J,. Acute exercise improves cognition in the depressed elderly: the effect of dual-tasks. Clinics (Sao Paulo) 2011; 66 (9): 1553-1557.
85. Knochel C, Oertel-Knochel V, O'Dwyer L, et al. Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog Neurobiol 2012; 96 (1): 46-68.
86. Thomas AJ, Gallagher P, Robinson LJ, et al. A comparison of neurocognitive impairment in younger and older adults with major depression. Psychol Med 2009; 39 (5): 725-733.
87. Herrmann LL, Le MM, Ebmeier KP,. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry 2008; 79 (6): 619-624.
88. Gildengers AG, Butters MA, Chisholm D, et al. Cognition in older adults with bipolar disorder versus major depressive disorder. Bipolar Disord 2012; 14 (2): 198-205.
89. McDermott LM, Ebmeier KP,. A meta-analysis of depression severity and cognitive function. J Affect Disord 2009; 119 (1-3): 1-8.
90. Withall A, Harris LM, Cumming SR,. A longitudinal study of cognitive function in melancholic and non-melancholic subtypes of major depressive disorder. J Affect Disord 2010; 123 (1-3): 150-157.
91. Gallagher P, Robinson LJ, Gray JM, Porter RJ, Young AH,. Neurocognitive function following remission in major depressive disorder: potential objective marker of response? Aust N Z J Psychiatry 2007; 41 (1): 54-61.
92. Liu IC, Chiu CH, Yang TT,. The effects of gender and a co-occurring depressive disorder on neurocognitive functioning in patients with alcohol dependence. Alcohol Alcohol 2010; 45 (3): 231-236.
93. McIntyre RS, Kenna HA, Nguyen HT, et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther 2010; Apr 13; 27 (2): 63-80.
94. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"? Ann Clin Psychiatry 2007; 19 (4): 257-264.
95. Lemos-Miller A, Kearney CA,. Depression and ethnicity as intermediary variables among dissociation, trauma-related cognitions, and PTSD symptomatology in youths. J Nerv Ment Dis 2006; 194 (8): 584-590.
96. Riso LP, Miyatake RK, Thase ME,. The search for determinants of chronic depression: a review of six factors. J Affect Disord 2002; 70 (2): 103-115.